IXICO's TechBio Pivot Gains Traction with Record Orders and a Medidata Partnership

H1 revenue up 23%, order book at record £18.1M, and a fresh £10M war chest to productize its AI platform into a larger addressable market.

IXI.L · Earnings Call · 2026-05-21

From Imaging CRO to Platform Player

IXICO has long been known as a leading imaging CRO in neurology, but its latest interim results signal a decisive shift. The company is now executing on a TechBio strategy that aims to transform its IXI platform from an internal tool into a licensable product — expanding its addressable market from an estimated $100 million bespoke iCRO niche to a 3–4x larger opportunity by partnering with big CROs, data players, and software providers. The move comes with a freshly filled £10M raise and a concrete partnership with Medidata (a Dassault Systèmes company) — a major validation of its technology. The numbers support the urgency. First-half revenue grew 23% year-on-year to £3.9M, beating the 15% full-year guide, and the order book hit a record £18.1M, up 31% since September. As CEO Bram Goorden emphasized, “this order book now fuels 95% of the revenues, which are out there with a guidance of GBP 7.5 million” — Bram Goorden, Chief Executive Officer · 2026-05-21 — giving shareholders rare visibility for a micro-cap. CFO Grant Nash reinforced the strategic intent behind the raise: “our expectation is that this company will be profitable and will be generating cash by '29” — Grant Nash, Chief Financial Officer and Chief Operating Officer · 2026-05-21, but only after deliberate investment.

The Productization Roadmap

What's new here is the concreteness. In December, the company had only floated the recurring revenues idea; now it has a defined road map. By the end of the year, IXICO aims to have 2–3 commercially validated products for licensing, and it will begin the FDA pathway for software-as-a-medical-device in 2027. The Medidata collaboration is the proof point: Medidata's Rave platform will integrate IXI's analytics, giving both companies a one-stop shop for clinical trial data management and imaging analysis. As Goorden put it,

So when we talk about the TechBio strategy, we're basically talking about expanding our addressable market... we want to go on that blue line that you see here on this chart, which basically will, at the one hand, increase revenues, increase growth. And those revenues will also become, if you wish, more sound revenues as they're highly relying on analytics and therefore, are going to present higher margins and will also be represented through different size of contracts, whereby they will become recurring revenues.
Bram Goorden, Chief Executive Officer · 2026-05-21

This is a clear departure from the pure CRO model the company has run since its inception. Even the prior call's language was more tentative: “we have deliberately taken the decision and was a key part of the capital raise we did 12 months ago to move this business not just to profitability, but to sustainable profitability” — Grant Nash, Chief Financial Officer (CFO) and Chief Operating Officer (COO) · 2025-12-10 — that was about profitability, not about productization. Now the company is actively building a second revenue engine.

The Moat: Data and Endorsements

The pivot is not a leap into the unknown — IXICO has a 20-year archive of brain images and proprietary algorithms, and it has added six new key opinion leaders plus the Michael J. Fox Foundation to its roster. The AI-driven capabilities are already deployed in its platform, and the company is confident that its data assets provide a durable edge. Even as large language models proliferate, Goorden argues, “the moat is not so much around AI only. It's also about the data that inform the AI.” — Bram Goorden, Chief Executive Officer · 2026-05-21 That data — hundreds of thousands of images and partnerships with groups like the Global Alzheimer's Platform — is difficult to replicate.

What to Watch

The company still has work to do: it reported an EBITDA loss of £0.5M for the half, and while the order book provides 95% coverage of FY26 revenue, the real test will be whether it can convert its pipeline of Alzheimer's and Parkinson's projects into contracted orders and then into the new recurring revenues that the TechBio strategy promises. The Medidata deal, if executed well, could be a template for many more such partnerships, fundamentally changing the company's risk profile. For a company with a market cap of just under £19M, the opportunity is outsized — and so is the risk.